Forty Seven Inc. (FTSV)’s Financial Results Comparing With Bioblast Pharma Ltd. (NASDAQ:ORPN)

Since Forty Seven Inc. (NASDAQ:FTSV) and Bioblast Pharma Ltd. (NASDAQ:ORPN) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership of both companies.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Forty Seven Inc. N/A 0.00 65.49M -2.06 0.00
Bioblast Pharma Ltd. N/A 0.00 3.33M -1.80 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Forty Seven Inc. and Bioblast Pharma Ltd.


Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Forty Seven Inc. 0.00% 0% 0%
Bioblast Pharma Ltd. 0.00% -132.9% -111.6%


The Current Ratio and Quick Ratio of Forty Seven Inc. are 11.9 and 11.9 respectively. Its competitor Bioblast Pharma Ltd.’s Current Ratio is 7.9 and its Quick Ratio is 7.9. Forty Seven Inc. can pay off short and long-term obligations better than Bioblast Pharma Ltd.

Institutional and Insider Ownership

The shares of both Forty Seven Inc. and Bioblast Pharma Ltd. are owned by institutional investors at 64.6% and 18.6% respectively. Insiders owned 21.4% of Forty Seven Inc. shares. Comparatively, Bioblast Pharma Ltd. has 37.04% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Forty Seven Inc. -0.43% 42.31% 34.16% 0% 0% 22.92%
Bioblast Pharma Ltd. -8.66% -14.07% -8.23% -48.9% -41.41% -49.26%

For the past year Forty Seven Inc. has 22.92% stronger performance while Bioblast Pharma Ltd. has -49.26% weaker performance.


Forty Seven Inc. beats on 4 of the 6 factors Bioblast Pharma Ltd.

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. It develops Trehalose 90mg/mL IV solution, a protein stabilizer and autophagy enhancer to treat patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company was founded in 2012 and is headquartered in Tel Aviv, Israel.